A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Abbott796 enrolled

Overview

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in patients with rheumatoid arthritis

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

796

Conditions

Rheumatoid Arthritis

Interventions

Adalimumab 40 mg subcutaneous (SC) every other week (EOW)BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completion of a previous D2E7 study * Subject is in good health (Investigator discretion) with a recent stable medical history Exclusion Criteria: * Former enrollment in this trial (DE018) * Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study * Female subject who is pregnant or breast feeding or considering becoming pregnant.

Outcomes

Primary Outcomes

Clinical response indicators

Time frame: 5 years

Secondary Outcomes

Safety parameters

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.